Association of hypertension with mortality in patients hospitalised with COVID-19

• DOI: 10.1136/openhrt-2021-001853
• Publication Date: 2021-12-07T22:25:18Z
• Authors: Kunwardeep S Bhatia; Hari P Sritharan; Jonathan Ciofani; Justin Chia; Usaid K Allahwala; Karina Chui; Daniel Nour; Sheran Vasanthakumar; Dhanvee Khandadai; Pavithra Jayadeva; Rohan Bhagwandeen; David Brieger; Christopher Choong; Anthony Delaney; Girish Dwivedi; Benjamin Harris; Graham Hillis; Bernard Hudson; George Javorski; Nigel Jepson; Logan Kanagaratnam; George Kotsiou; Astin Lee; Sidney T Lo; Andrew I MacIsaac; Brendan McQuillan; Isuru Ranasinghe; Antony Walton; James Weaver; William Wilson; Andy S C Yong; John Zhu; William Van Gaal; Leonard Kritharides; Clara K Chow; Ravinay Bhindi
• Keywords: Adult; Male; 610; Angiotensin-Converting Enzyme Inhibitors; Comorbidity; Risk Assessment; Angiotensin Receptor Antagonists; 03 medical and health sciences; 0302 clinical medicine; Prevalence; Diseases of the circulatory (Cardiovascular) system; Humans; Hospital Mortality; Registries; Antihypertensive Agents; Aged; Aged, 80 and over; Australia; COVID-19; Middle Aged; Prognosis; Cardiac Risk Factors and Prevention; 3. Good health; Hospitalization; RC666-701; Hypertension; Female

Objective To assess whether hypertension is an independent risk factor for mortality among patients hospitalised with COVID-19, and to evaluate the impact of ACE inhibitor angiotensin receptor blocker (ARB) use on in a background hypertension. Method This observational cohort study included all index hospitalisations laboratory-proven COVID-19 aged ≥18 years across 21 Australian hospitals. Patients suspected, but not were excluded. Registry data analysed in-hospital comorbidities including hypertension, baseline treatment inhibitors or ARBs. Results 546 consecutive (62.9±19.8 old, 51.8% male) enrolled. In multivariable model, significant predictors age (adjusted OR (aOR) 1.09, 95% CI 1.07 1.12, p<0.001), heart failure cardiomyopathy (aOR 2.71, 1.13 6.53, p=0.026), chronic kidney disease 2.33, 1.02 5.32, p=0.044) obstructive pulmonary 2.27, 1.06 4.85, p=0.035). Hypertension was most prevalent comorbidity (49.5%) independently associated increased 0.92, 0.48 1.77, p=0.81). Among 1.37, 0.61 3.08, p=0.61) ARB 0.64, 0.27 1.49, p=0.30) mortality. Conclusions pre-existing Similarly, ARBs had no association